{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:51:10Z","timestamp":1790819470656,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001543","name":"Children&apos;s Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005848","name":"Henry Luce Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011719","name":"Bone Cancer Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejmech.2023.115244","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:35:01Z","timestamp":1677756901000},"page":"115244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability"],"prefix":"10.1016","volume":"251","author":[{"given":"Kaluvu","family":"Balaraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eryn","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Pilicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezen","family":"Atasoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Molotkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handan","family":"Sevim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purushottam B.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"\u00dcren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-3753","authenticated-orcid":false,"given":"Christian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejmech.2023.115244_bib1","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/j.1460-2075.1989.tb08485.x","article-title":"The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product","volume":"8","author":"Gelin","year":"1989","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115244_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng1194-285","article-title":"PBDX is the XG blood group gene","volume":"8","author":"Ellis","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2023.115244_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-1119(03)00401-3","article-title":"Cloning, genomic organization, alternative transcripts and expression analysis of CD99L2, a novel paralog of human CD99, and identification of evolutionary conserved motifs","volume":"307","author":"Suh","year":"2003","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115244_bib4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/emm.2007.81","article-title":"Detection of homodimer formation of CD99 through extracelluar domain using bimolecular fluorescence complementation analysis","volume":"39","author":"Choi","year":"2007","journal-title":"Exp. Mol. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115244_bib5","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.1203062","article-title":"Interaction of CD99 with its paralog CD99L2 positively regulates CD99L2 trafficking to cell surfaces","volume":"191","author":"Nam","year":"2013","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115244_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3858\/emm.2010.42.5.037","article-title":"Interaction between the mouse homologue of CD99 and its ligand PILR as a mechanism of T cell receptor-independent thymocyte apoptosis","volume":"42","author":"Park","year":"2010","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115244_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/genes9030159","article-title":"CD99: a cell surface protein with an oncojanus role in tumors","volume":"9","author":"Manara","year":"2018","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115244_bib8","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U","article-title":"MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration","volume":"67","author":"Ambros","year":"1991","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115244_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00428-009-0842-7","article-title":"Histological heterogeneity of Ewing's sarcoma\/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support","volume":"455","author":"Llombart-Bosch","year":"2009","journal-title":"Virchows Arch."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115244_bib10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1365-2141.1999.01426.x","article-title":"CD99 (MIC2) expression in paediatric B-lineage leukaemia\/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis","volume":"105","author":"Dworzak","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115244_bib11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/sj.leu.2403303","article-title":"On behalf of the I-BFM-ALL-FCM-MRD-Study Group, CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease","volume":"18","author":"Dworzak","year":"2004","journal-title":"Leukemia"},{"issue":"374","key":"10.1016\/j.ejmech.2023.115244_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2025","article-title":"CD99 is a therapeutic target on disease stem cells in myeloid malignancies","volume":"9","author":"Chung","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115244_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","article-title":"Ewing sarcoma","volume":"4","author":"Gr\u00fcnewald","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115244_bib14","first-page":"317","article-title":"Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30\/32MIC2","volume":"139","author":"Fellinger","year":"1991","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115244_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0046-8177(94)90203-8","article-title":"Ewing's sarcoma\u2014routine diagnostic utilization of MIC2 analysis: a pediatric oncology group\/children's cancer group intergroup study","volume":"25","author":"Perlman","year":"1994","journal-title":"Hum. Pathol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115244_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00000478-199405000-00008","article-title":"Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30\/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma","volume":"18","author":"Weidner","year":"1994","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115244_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/15513819609168678","article-title":"EWS\/FLI-1 fusion transcript detection and MIC2 immunohistochemical staining in the diagnosis of ewing's sarcoma","volume":"16","author":"Lee","year":"1996","journal-title":"Pediatr. Pathol. Lab. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115244_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/(SICI)1097-0339(199812)19:6<410::AID-DC2>3.0.CO;2-Z","article-title":"Diagnostic utility of MIC-2 immunocytochemical staining in the differential diagnosis of small blue cell tumors","volume":"19","author":"Halliday","year":"1998","journal-title":"Diagn. Cytopathol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115244_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI36667","article-title":"CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis","volume":"120","author":"Rocchi","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115244_bib20","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/sj.onc.1209300","article-title":"Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells","volume":"25","author":"Kreppel","year":"2006","journal-title":"Oncogene"},{"issue":"30","key":"10.1016\/j.ejmech.2023.115244_bib21","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1038\/onc.2015.463","article-title":"CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-\u03baB signaling","volume":"35","author":"Ventura","year":"2016","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115244_bib22","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0002-9440(10)65707-0","article-title":"Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in ewing's sarcoma cells","volume":"153","author":"Sohn","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115244_bib23","first-page":"5134","article-title":"CD99 engagement: an effective therapeutic strategy for ewing Tumors1","volume":"60","author":"Scotlandi","year":"2000","journal-title":"Cancer Res."},{"issue":"48","key":"10.1016\/j.ejmech.2023.115244_bib24","doi-asserted-by":"crossref","first-page":"79925","DOI":"10.18632\/oncotarget.13160","article-title":"CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R\/RAS\/Rac1 signaling","volume":"7","author":"Manara","year":"2016","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.ejmech.2023.115244_bib25","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/s41388-017-0080-4","article-title":"Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99","volume":"37","author":"\u00c7elik","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115244_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253170","article-title":"Clofarabine induces ERK\/MSK\/CREB activation through inhibiting CD99 on Ewing sarcoma cells","volume":"16","author":"Sevim","year":"2021","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ejmech.2023.115244_bib27","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1073\/pnas.77.11.6865","article-title":"Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo","volume":"77","author":"Carson","year":"1980","journal-title":"P. Natl. A. Sci. USA."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115244_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2004.03.007","article-title":"Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia","volume":"210","author":"Lindemalm","year":"2004","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115244_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nrd2055","article-title":"Discovery and development of clofarabine: a nucleoside analogue for treating cancer","volume":"5","author":"Bonate","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115244_bib30","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.4049\/jimmunol.1001707","article-title":"A cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation","volume":"185","author":"Balsley","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115244_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/anie.200904529","article-title":"A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins","volume":"49","author":"Malesevic","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115244_bib32","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/sj.onc.1210897","article-title":"A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion","volume":"27","author":"Tsutsumi","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115244_bib33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/0008-5472.CAN-05-2591","article-title":"Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms","volume":"66","author":"Wu","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115244_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.freeradbiomed.2012.09.018","article-title":"Hydropropidine: a novel, cell-impermeant fluorogenic probe for detecting extracellular superoxide","volume":"54","author":"Michalski","year":"2013","journal-title":"Free Radic. Biol. Med."},{"issue":"44","key":"10.1016\/j.ejmech.2023.115244_bib35","doi-asserted-by":"crossref","first-page":"14970","DOI":"10.1002\/chem.201302002","article-title":"Development of luminescent coelenterazine derivatives activatable by beta-galactosidase for monitoring dual gene expression","volume":"19","author":"Lindberg","year":"2013","journal-title":"Chemistry"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115244_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jconrel.2012.04.018","article-title":"In vivo temperature controlled ultrasound-mediated intracellular delivery of cell-impermeable compounds","volume":"161","author":"Yudina","year":"2012","journal-title":"J. Contr. Release"},{"issue":"11","key":"10.1016\/j.ejmech.2023.115244_bib37","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/asia.200900233","article-title":"Benzenesulfonamidoquinolino-beta-cyclodextrin as a cell-impermeable fluorescent sensor for Zn2+","volume":"4","author":"Zhang","year":"2009","journal-title":"Chem. Asian J."},{"issue":"15","key":"10.1016\/j.ejmech.2023.115244_bib38","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cmdc.201900348","article-title":"Synthesis of substituted 5\u2032-aminoadenosine derivatives and evaluation of their inhibitory potential toward CD73","volume":"14","author":"Ghoteimi","year":"2019","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115244_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bmc.2017.11.022","article-title":"Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: structure-based virtual screening, optimization and biological evaluation","volume":"26","author":"Qiu","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115244_bib40","unstructured":"L. Chen, J. Li, E.B. Sjogren, R.J. Billedeau, Ectonucleotidase Inhibitors and Methods of Use Thereof. WO20180491452018."},{"key":"10.1016\/j.ejmech.2023.115244_bib41","series-title":"Ectonucleotidase Inhibitors and Methods of Use Thereof","author":"Billedeau","year":"2018"},{"issue":"45","key":"10.1016\/j.ejmech.2023.115244_bib42","doi-asserted-by":"crossref","first-page":"18581","DOI":"10.1021\/ja309650u","article-title":"Organocatalytic carbonyl-olefin metathesis","volume":"134","author":"Griffith","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"22","key":"10.1016\/j.ejmech.2023.115244_bib43","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1021\/jm070362i","article-title":"First example of phosphoramidate approach applied to a 4\u2018-substituted purine nucleoside (4\u2018-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus Hepatitis C virus","volume":"50","author":"Perrone","year":"2017","journal-title":"J. Med. Chem."},{"issue":"55","key":"10.1016\/j.ejmech.2023.115244_bib44","doi-asserted-by":"crossref","first-page":"32165","DOI":"10.1039\/C9RA07567D","article-title":"Structure-based design of nucleoside-derived analogues as sulfotransferase inhibitors","volume":"9","author":"Kershaw","year":"2019","journal-title":"RSC Adv."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115244_bib45","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/jm00086a013","article-title":"Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides","volume":"35","author":"Maag","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115244_bib46","unstructured":"L. Beigelman, J. Deval, D.B. Smith, G. Wang, V. K. Rajwanshi, Preparation of Azido Nucleosides and Nucleotide Analogs as Antiviral Agents. US20120070415."},{"key":"10.1016\/j.ejmech.2023.115244_bib47","unstructured":"The Conversions Were Typically High and the Low Yields of Some Iodides Result from Loss during Work-Up."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115244_bib48","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jbmr.2141","article-title":"CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1\/2","volume":"29","author":"Sciandra","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115244_bib49","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1091\/mbc.e05-10-0971","article-title":"CD99 acts as an oncosuppressor in osteosarcoma","volume":"17","author":"Manara","year":"2006","journal-title":"Mol. Biol. Cell"},{"issue":"15","key":"10.1016\/j.ejmech.2023.115244_bib50","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/onc.2013.152","article-title":"CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity","volume":"33","author":"Zucchini","year":"2014","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.ejmech.2023.115244_bib51","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"issue":"6141","key":"10.1016\/j.ejmech.2023.115244_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Molina","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115244_bib53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12079-017-0445-z","article-title":"CD99 at the crossroads of physiology and pathology","volume":"12","author":"Pasello","year":"2018","journal-title":"J. Cell Commun. Signal."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115244_bib54","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1128\/MCB.00332-15","article-title":"Ezrin binds to DEAD-box RNA Helicase DDX3 and regulates its function and protein level","volume":"35","author":"\u00c7elik","year":"2015","journal-title":"Mol. Cell Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:48:53Z","timestamp":1759330133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423002106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":54,"alternative-id":["S0223523423002106"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115244","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115244"}}